Directors' Blog

Antibiotic resistance is looming but we can protect the children
In another life I used to sit on teams that developed something called ‘clinical guidance’. We would draw together published evidence and make recommendations on what best practice should look like. I sat on one such group for rheumatic fever.
Rheumatic fever (RF) is a disease now seen mainly in developing countries (apart, of course, from the poor pockets of New Zealand where it runs at near epidemic rates). If rheumatic fever is not caught early, it leads to rheumatic heart disease (RHD) that in turn leads to serious heart damage – the sort of damage that can see people die in their late 30s.
On this rheumatic fever clinical guidance group that I sat on, I heard a story about the antibiotics that are used to treat the disease. I heard that many of the kids with rheumatic fever live rurally and getting treatment to them is a challenge. I heard that the antibiotics needed to be kept at temperatures lower than a few degrees. I heard that these antibiotics are often driven around the dusty roads of rural New Zealand in the height of a Kiwi summer, eventually getting to families warm and possibly no longer effective. What I heard was that kids who needed the antibiotics the most were being let down by basic logistical stuff-ups.
Is this story representative? Are vulnerable low-income children missing out on antibiotics? And if children are already missing out on antibiotics when they need them in New Zealand, how will population-wide antibiotic resistance affect these children? Children who, coming from low income families, are already at greater risk of infectious disease than other children in New Zealand?
The story for low-income kids and antibiotics is complex & resistance is not going to make things better
Children living on low incomes in New Zealand have more infections (requiring antibiotic treatment) than other children. Rheumatic fever is one disease they contract at higher rates, especially as overcrowding and poor quality housing continues unabated in Auckland. But we also know from the Child and Youth Epidemiology Service, who reports on child health in New Zealand each year, that skin infections plague children from poorer communities. We also know that respiratory infections put them in hospital at a much greater rate than others. And when diseases like measles break out, they tend to do so in low-income communities, with the bulk of the health effects being felt by the children of low -income families. These are the children who need antibiotics and need them to work. Even with antibiotics, children are still dying in New Zealand from diseases of the third world.
Poor children need antibiotics more than other children, but are they getting them?
The situation is complex. We have data showing us that antibiotic prescribing in Counties Manukau in Auckland (a large low-income community) is greatest for those living in overcrowded households [1]. Overcrowding is one of the indicators of poverty in New Zealand.
Below we can see the relationship between antibiotic prescribing and overcrowded households in Counties Manukau. We see as the ratio goes up (representing more people in a bedroom) antibiotic scripts rise too. This finding is understandable in the context of how infectious diseases spread – through close contact with other infected people.
But does the higher prescribing rate of antibiotics for the vulnerable mean all the children who need them are also getting them? A prescription for antibiotics is not a measure of antibiotics used. We can look at the dispensing of antibiotic use for some clues.
Researchers examined the dispensing of antibiotics (pharmacies filling a prescription) in another part of New Zealand. The town was a rural town at least an hour from other towns with a pharmacy. Researchers found that individuals living in lower income areas of that community were much less likely to be dispensed antibiotics.[2]
So we see that infections are higher for low-income children in New Zealand, and prescriptions may also be higher, but that actual use may be lower for this group.
Low-income children do have the worst access to healthcare in New Zealand
The data present a complex picture, but not one those working in health are unfamiliar with. It highlights what we see across all societies – those that need healthcare the most may be accessing it the least. We call it the inverse care law.
We can speculate based on this evidence what is happening with low-income children in New Zealand. It may be that children of low-income families are getting to the GP but not getting the antibiotics on board. It may be that even getting to the GP is such a challenge that low-income children are not being seen till very late – we certainly know that low-income children see medical professionals a lot later down the path of an infectious disease making treatment more difficult and spread and recurrence more likely.
It may be that low-income families cannot easily access the antibiotics even once they are prescribed. We know that in New Zealand the children who don’t get to the GP because they have no transport (a measure of material deprivation & poverty) are the children of low-income parents, as the data below demonstrates.
New Zealand has a government funded primary healthcare system, with free GP visits for children under 13 and low cost prescriptions. But in reality, there is an imbalance in who accesses this funded healthcare. It not just healthcare itself that costs families – the opportunities to access the care also costs: time off work; access to transport; being free of other health debts and social stigma; having someone who can care for any other children. These are all resources a parent needs to be able to draw upon to access healthcare for their child. In many cases, low-income families have fewer of all of these resources. While the data has gaps, it certainly indicates that there is likely to be a problem in terms of low-income children’s access to and use of antibiotics when they need them.
What happens when we add antibiotic resistance into the mix?
Nothing good. For children who need antibiotics the most, resistance has the most serious impact. For a group of children who are already disadvantaged by being poor, we have at least always had the hope that, if they can equitably access timely treatment, we can overcome some of the disadvantage they suffer. With resistance looming this will not be the case, and the children who will die at the greatest rate from what are now just everyday infections will of course be those already getting the worst deal from the imbalance in New Zealand society. But we can do something about this.
What can be done?
As always the ambulance parked at the bottom of the cliff will not assist us here. Research into antibiotic alternatives needs funding, and a huge reduction in unnecessary antibiotic use is needed (including in animals and farming).
However, there is something we can do right now for children living on low-incomes – we can correct the imbalance in their health outcomes through strong policy. Research tells us there are many effective ways to address this imbalance, and most of them lie outside of the control of the health workforce.
Bringing families with children up over the various poverty lines using unconditional cash assistance is an area that has significant potential to improve children’s health. Housing affordability, quality and access is another area with serious potential to improve low-income children’s health. The best evidence shows that improvements to the physical aspects of the home (e.g., ensuring it is the appropriate size for a family, it can affordably be kept warm, it is insulated and not damp) improves health (especially in those with existing respiratory illness), may improve and promote relationships in the family, and may reduce absences from school or work. The findings are especially applicable in low-income households where the need is greatest.[3]
The end of antibiotics as we know is upon us. However, in the time between their discovery and their demise, let us finally deliver for low-income children a good society, one that ensures we are all already in the same boat as we work to find solutions together.
References
[1] Walls, G., Vandal, A. C., du Plessis, T., Playle, V., & Holland, D. J. (2015). Socioeconomic factors correlating with community antimicrobial prescribing. NZ Med J, 128(1417), 16-23.
[2] Norris, Pauline, Gordon Becket, and Denise Ecke. “Demographic variation in the use of antibiotics in a New Zealand town.” The New Zealand Medical Journal (Online) 118.1211 (2005).
[3] Thomson H, Thomas S, Sellstrom E, Petticrew M. Housing improvements for health and associated socio-economic outcomes. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD008657. DOI: 10.1002/14651858.CD008657.pub2.
About
Dr Jess Berentson-Shaw works at the Morgan Foundation Policy Think Tank and writes about science, children and families at The Spinoff Parents. You can follow her on Twitter @DrJessBerentson
What is InfectedNZ?
Hey, Aotearoa. It’s time we had a chat about infectious diseases and what we’re going to do about the looming antimicrobial armageddon. That’s why we’ve asked leading health, social and economic researchers, and people with personal stories, to help us get real about our vulnerability and discuss solutions. Follow their blogs right here at tepunhahamatatini.ac.nz and watch the conversation spread across social media with #infectedNZ.
Backing it all up, wherever possible, is data from the good folk at Figure.NZ. Their super duper charts are based on data sourced from public repositories, government departments, academics and corporations. Check out their #infectedNZ data board and sign-up to create your very own data board on any topic that floats your boat.

Living with MRSA
Wash your hands all you want. Don’t touch things. Clean your cuts and grazes. Be careful all you can… but it won’t make any difference. An open wound will grow; it will cause rashes on your body and your skin to blister and weep. Once it’s in your blood stream, it goes wild, living in there like an uninvited guest crashing your dinner party.
It smells. I can smell it a mile away. Doctors laugh at you, but it definitely has its own smell. It stinks and to get rid of it, to try and get it to leave you completely, is like being entrenched in a war where no matter how hard you try the other side is always tougher.
I spit the words when I say them as it has haunted my life and my family’s life for so long. It enveloped my every waking moment, and every sleepless night, as I wished moment after moment it had never come into our lives.
It’s MRSA, a form of staph bug – a superbug which has nothing I deem “super” about it. To me, super is like a “super hero”, but the only hero when it comes to MRSA is those who battle it or those who are trying to cure it.
My little girl lived in hospital a long time battling gastrointestinal failure and the complications that accompany it. We were definitely no strangers to infections, spending weeks on end on all order of antibiotics for every different thing over years and years. That was my biggest worry then, and now. People used to say MRSA, MSBL, C.diff, and I used to just switch off; my child didn’t have them, so it didn’t matter.
Then one day, while she battled a burst gall bladder and just wouldn’t show signs of improvements as she had infection after infection, a doctor came into the room, gowned, gloved, and masked and said she has MRSA in her blood stream and it’s growing in her line and tubes.
Oh shit, I said. That’s all I said. I still didn’t register how much it would affect our lives.
We lived in the hospital and were always around and about, playing with nurses, in the play room; anything to pass the time. Now, once she recovered from the gall bladder incident, we couldn’t play; she still grew MRSA. Too many lines and tubes. No more playing with other children in hospital. No more playroom. We were stuck – isolated with a bug that was growing more resistant by the day and scared of spreading it around. And, of course, following strict hospital protocol around such bugs.
But, reality was, that’s nothing compared to the impact it had on my child physically. No longer are you just battling a medical condition but a serious infection on top. It rules your life and all the choices you make.
It leaks and oozes. Then you change a dressing and after multiple changes it then gets raw and oozy. Years of constant infections followed, and traumatic moments that I won’t relive here.
You think with an infection that doctors just get an antibiotic and treat it. If that doesn’t work, they will have another. The thing about a bug like this is you can get to the end of antibiotics, and those IVs take longer and longer before a solution is found. Within a week, after more and more attempts, it then doesn’t work at all. The bug lays dormant then sneaks up and flares up when you least expect it. One day nothing. Then you look the next day and see the familiar pale yellow ooze leaking out from a line and your heart sinks. You know it will get worse before it gets better.
The other thing people don’t get is the toll endless antibiotics takes on a body: thrush, reactions, tummy pain, puffiness, blowing lines. Endless and yet unavoidable. The constant fear of what next eats away at you as well as the constant worry about treatments not working. Even short term IV lines grew MRSA as we lost line after line and our vein access went from minimal to pretty much nothing.
The thing is, it’s a bug, you catch it. That brings a whole different sort of grief and anger compared to a condition you are born with or develop. Anger ruled my life. When MRSA flared up, I was often so scared as the violent convulsions from temperatures would take hold from another infection in the line. It had to be someone’s fault. I found people to blame and, to an element, I still do. But it’s nothing compared to the guilt and blame you place on yourself. As a mother, I should protect my children – the most precious things in my life.
Yet, while in my care, my child contracted a bug that was ravishing her poor little body. Did I not wash my hands enough? Did I not watch procedures close enough? Should she have sat on the ground when she did? So many stupid questions. When I’m not exhausted, and as life moves on, I know it’s a bug that’s everywhere. The longer you are in hospital, the more immune-suppressed you are, or just pot luck, you’re likely to contract a superbug. I just wish it hadn’t grown on my child. I wish it didn’t exist at all.
We don’t have a line now. The last growth of MRSA was followed by thrush in her blood stream and it meant the final access was to be removed. Reality is, any line is going to be an area likely to grow this bug.
The not sleeping at night as you check continuously for a line infection; the constant changing of painful dressing; the fear that this could be in her blood (and not picked up earlier) all dulled, as the risk is so much lower. But, unfortunately, it still rears its head, but in more fiddly ways. A skinned knee ends up more manky, the longed-for pierced ears mucky and taking longer to heal. It’s a relief to sleep easier at night but also a battle to keep a child with gut failure line-free.
Something good I realised, just the other day, was how improved her quality of life has become now that she hasn’t got a line oozing MRSA continuously. That bug took such a toll on her body that she was bloated and puffy from constant meds.
It’s been a really big and cruel lesson to learn how important the research being done to treat and cure Staph bugs is. It’s something you just wish no one had to deal with. It’s something I wish my family never had to deal with.
We need to find a cure.
About
This post was provided by parent Tiff Mora.
What is InfectedNZ?
Hey, Aotearoa. It’s time we had a chat about infectious diseases and what we’re going to do about the looming antimicrobial armageddon. That’s why we’ve asked leading health, social and economic researchers, and people with personal stories, to help us get real about our vulnerability and discuss solutions. Follow their blogs right here at tepunhahamatatini.ac.nz and watch the conversation spread across social media with #infectedNZ.
Backing it all up, wherever possible, is data from the good folk at Figure.NZ. Their super duper charts are based on data sourced from public repositories, government departments, academics and corporations. Check out their #infectedNZ data board and sign-up to create your very own data board on any topic that floats your boat.

HIV prevention in NZ: on a knife edge
HIV seems like a scourge of the eighties, but today new HIV diagnoses and the costs of medication are escalating out of control in New Zealand. The world’s most dangerous infectious disease epidemic of the modern era is being revived, fuelled by invisibility, indifference and inaction.
HIV has a terrifying ability to evolve and evade control when our guard is down. The virus has killed 40 million people worldwide. 2.5 million people contracted HIV in 2015. Three decades later we still have no vaccine and no cure.
The fact is HIV is exceptionally well adapted to spread between humans. The virus is transmitted through sexual behaviour and injecting drugs, behaviours that are not easy to change. Infection is often asymptomatic, so people need to be tested to confirm if they have the virus. HIV is most infectious shortly after someone becomes infected, when they are probably unaware that they have it. Finally, HIV is subject to cultural taboos, triggering embarrassment and discouraging open conversations.
So despite three decades of scientific knowledge we’re again witnessing expanding epidemics across the globe; from mature epidemics in the UK to new epidemics like the Philippines, where transmission since 2005 has been explosive.
The latest trends here are alarming. Last year New Zealand recorded the highest number of annual HIV diagnoses ever, the fourth increase in a row. In gay and bisexual men, who account for 80% of our epidemic, annual HIV cases contracted locally are now four times higher than at the epidemic low point in 2000.
Treatment expenditure is also soaring, doubling in the last 6 years from $16.8 million in 2011 to $32.8 million in 2016. It’s estimated that one person diagnosed with HIV at age 20 could cost Pharmac over $800,000 in antiretroviral treatments over their lifetime. It’s why HIV prevention makes great fiscal sense: for every infection averted we’d be able to fund other much needed medication for New Zealanders.
It’s disappointing because we’ve got a proud record that risks being squandered. When HIV first made it to New Zealand over thirty years ago, the country responded boldly. Interventions were based on evidence and we agreed on rational policies, bi-partisan political engagement and urgency. Moralism was rejected in favour of science and cooperation.
The result was an international infection control success story: New Zealand was one of the first countries in the world to report a decline in AIDS. We had among the lowest rates of HIV diagnoses in gay and bisexual men internationally, and we still have the lowest rate of HIV among people who inject drugs.
HIV’s comeback is driven by a roll-call of big issues confronting contemporary societies.
Internet dating’s hyper-connectivity has been exploited by HIV and other sexually transmitted infections, spreading through sexual networks in clusters and to individuals previously distant from transmission epicentres.
Social media could be used to empower HIV prevention but Google, Facebook and Apple have blocked condom and HIV testing advertisements due to their “offensive content”. That means content has to be clinical and sanitised, reducing its relevance to target audiences.
Pornography is increasingly accessible and unregulated, but tends to promote condomless sex.
Pharmaceuticals have thankfully transformed life expectancy to near-normal with early diagnosis. But they also make HIV seem less visible and less threatening, and their expense ties up scarce health resources, leaving less money for safe sex programmes and research.
Stigma compounds that invisibility, silencing the voice of people living with HIV and deterring those at risk from seeking testing and prevention resources.
And rising consumption of recreational drugs, particularly methamphetamine, can facilitate unprotected sex and increases HIV transmission risks if unsterilised injecting equipment is shared.
The upshot is that nowadays HIV prevention operates in a very challenging environment. The accumulation of these small shifts and unintended consequences has allowed HIV to persist and reassert itself.
Likewise we shouldn’t forget why HIV is described as “the most political of diseases”. Controlling HIV means confronting established societal power structures head on, be they gender (men controlling women’s sexual norms), age (adults limiting young people’s access to sex education) or sexuality (gay communities denied sufficient resources because of heterosexism and homophobia).
In New Zealand, the greatest disparities in HIV are found among sexual orientation minorities. Our country has a favourable history promoting equal rights for gay communities so it’s unacceptable that the health status of the same groups doesn’t appear to enjoy the same commitment. If studies suggested that 1 in 15 heterosexual participants had HIV, with 1 in 5 of these undiagnosed, I’m left wondering if there’d be more urgency to respond?
What’s exciting and frustrating HIV experts here is that New Zealand could turn this around quickly. Scientific developments in the last two years mean that it is possible to virtually eliminate HIV transmission in New Zealand within 15 years. These developments centre on continued safe sex promotion, more frequent HIV testing, and adding two new tools to the mix.
The first tool is immediate antiretroviral treatment for people who test HIV positive. That’s because recent studies show that immediate rather than delayed treatment considerably improves long term health, and also suppresses the amount of virus in the body (called the HIV viral load) to the point where a person is almost uninfectious. In the “PARTNER” prospective cohort study, no linked transmissions were found from the HIV positive participants who had fully suppressed virus to their uninfected partner, even after 58,000 sex acts that didn’t involve condoms.
The second tool is offering the same HIV treatments as daily pre-exposure prophylaxis (PrEP) to the small number of uninfected individuals at very high risk of contracting HIV. Several studies have shown that PrEP reduces the risk of acquiring HIV by 86-92%, benefitting these individuals and also preventing chains of transmission to others: a population effect.
The World Health Organisation recently recommended immediate treatment on diagnosis, and countries such as the United States, France and Norway offer funded access to PrEP. In contrast, New Zealand government agencies have been slower to act, not yet approving immediate treatment or endorsing PrEP.
We urgently need re-engagement and action on HIV. We need to evolve and modernise our responses just as HIV has evolved from a frightening disease causing panic and fear, to a silent epidemic flying under the radar but harming our communities and health budgets.
At a time when we finally have the tools necessary to eradicate transmission, we literally can’t afford complacency to undo all the good work of our predecessors.
About
Peter Saxton is a Senior Research Fellow with an interest in HIV prevention and sexual health. He has a PhD in public health and is the inaugural New Zealand AIDS Foundation Fellow at the University of Auckland.
What is InfectedNZ?
Hey, Aotearoa. It’s time we had a chat about infectious diseases and what we’re going to do about the looming antimicrobial armageddon. That’s why we’ve asked leading health, social and economic researchers, and people with personal stories, to help us get real about our vulnerability and discuss solutions. Follow their blogs right here at tepunhahamatatini.ac.nz and watch the conversation spread across social media with #infectedNZ.
Backing it all up, wherever possible, is data from the good folk at Figure.NZ. Their super duper charts are based on data sourced from public repositories, government departments, academics and corporations. Check out their #infectedNZ data board and sign-up to create your very own data board on any topic that floats your boat.

Infertility: what’s it all about?
Infertility is defined as the inability for a couple having regular unprotected sexual intercourse to have a baby. Globally, the rate of fertility is declining but infertility still affects one in seven couples in New Zealand. In general, humans are generally not considered to be an especially fertile species, with a potential capability of 20-30% reproductive success with each menstrual cycle, albeit in a small window of opportunity for fertilisation of 5-6 days within each menstrual cycle. Fertility is highest in women in their 20s, and the rate of fertility declines with age, declining even more rapidly in a woman’s 40s, until the age of 50 where menopause occurs. This is when all of a woman’s eggs are exhausted within the ovaries and reproductive capacity ceases.
Women are increasingly delaying childbearing usually due to social and economic reasons. This, coupled with a gradual decline in fertility, means that other causes of infertility can become a significant issue, including having lifestyle factors such as obesity and smoking and sexually transmitted infections such as chlamydia and gonorrhea. These infections are further complicated by the fact that carriers of these infections can remain symptomless.
Chlamydia: the tip of the infertility iceberg
Chlamydia is the most common sexually transmitted infection in New Zealand, caused by the bacterium Chlamydia trachomatis. Chlamydia can be transmitted during vaginal, anal, or oral sex, and can be passed from an infected mother to her baby during childbirth. Chlamydia infections do not exhibit any symptoms in approximately 70% of women and 25% of men. While a chlamydia infection can be effectively cured with antibiotics, if left untreated there can be serious long-term reproductive consequences.
Approximately half of the women with a symptomless chlamydia infection will develop pelvic inflammatory disease, which is a generic term for infection of the uterus, fallopian tubes, ovaries and its surrounding tissues. Pelvic inflammatory disease can result in scarring and permanent damage of the reproductive organs, which can cause serious complications such as chronic pelvic pain, ectopic pregnancies (when an embryo implants in other parts of the female reproductive tract apart from the uterus), and infertility, especially with repeat infections. In men, if left untreated, chlamydia can cause pain, swelling and inflammation in the testes and urethra, and also lead to infertility.
According to a recent report to the Ministry of Health, laboratory surveillance efforts by the Institute of Environmental Science and Research Limited (ESR) showed that chlamydia was the most commonly reported sexually transmitted infection in 2014. With a national rate of 629 cases per 100,000 population, our rates are double those of Australia and the UK. 83% of cases reported were aged between 15 and 29 years. Chlamydia rates for males increased by 24.9% in the 40 years and over age group, and increased by 10% in the 25–29 years age group, but were generally stable in all other age groups. Chlamydia rates decreased in all age groups for females. However, there was more than twice the number of cases of chlamydia in women than in men. The national rate for females was 869 per 100,000 population (19,986 cases) compared to males that was 375 per 100,000 population (8275 cases).
Gonorrhoea: not quite the round of applause you’d like…
Gonorrhoea (commonly known as the clap) is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae, that can be transmitted during vaginal, anal, and oral sex, and from an infected mother to her baby during childbirth. The usual symptoms in men are a burning sensation when urinating and penile discharge. Women, on the other hand, may have vaginal discharge and pelvic pain. Gonorrhoea infections do not exhibit any symptoms in approximately 50% of women and up to 5% of men. If left untreated, the infection can spread locally, causing inflammation in the testes in men, or pelvic inflammatory disease in women. Gonorrhoea can also spread to affect joints and heart valves in the body.
According to the ESR survey, in 2014 our national gonorrhoea rate was 70 cases per 100,000 population, with 73% of those cases being in people aged between 15 and 29 years. The national rate for males was 77 per 100,000 population (1633 cases) and was higher than the national rate for females, that was 62 per 100,000 population (1367 cases). Between 2010 to 2014, there have been increasing rates of gonorrhea in both men and women, in a number of age groups; 40 years and over, and 25–29 years in men, and 15– 19 years and 30–34 years, in women. In this same time period, the numbers of gonorrhoea cases reported in women were highest in the 15–19 years and 20–24 years age groups, and in men were highest in the 25–29 years age group. More concerning is that antibiotic-resistant strains of N. gonorrhoeae have been identified in gonorrhea patients in New Zealand.
Reproductive health is an easily forgotten and underrated area of personal health care. Early recognition and effective treatment of sexually transmitted infections is an important protection against later problems with declining human fertility.
References:
References
- Gimenes F, Souza, RP, Bent, JC et al. Male infertility: a public health issue caused by sexually transmitted pathogens (2015). Nat Rev Urol. 11, 672-687.
- Menon S, Timms P, Allan JA, et al. Human and Pathogen Factors Associated with Chlamydia trachomatis-Related Infertility in Women (2015). Clin Microbiol Rev. 28(4):969-85.
- Newman L, Rowley J, Vander Hoorn S, et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting (2015). PLoS One. 10(12): e0143304.
- Sexually transmitted infections in New Zealand 2014. Institute of Environmental Science and Research Limited.
- Skerlev M, Čulav-Košćak I (2014). Gonorrhea: New challenges. Clin Dermatol. 32, 275-281.
- Markle W, Conti T, Kad M (2013). Sexually transmitted diseases. Prim Care. 40(3):557-87.
- Garnett G, (2008). How much infertility does chlamydia cause? Sex Transm Infect. 84, 157-158.
About
Dr Anita Muthukaruppan is a breast cancer researcher with the Department of Obstetrics and Gynaecology at the University of Auckland. She is a science geek with interests in gynaecological cancers, infertility, pregnancy, sexually transmitted infections, antibiotics, vaccines, carnivorous plants and quantum physics. Shea also loves Sir David Attenborough, Professor Stephen Hawking and Dr Emmett Brown.
Professor Andrew Shelling is Associate Dean (Research) at the Faculty of Medical and Health Sciences, and also head of the Medical Genetics Research Group in the Department of Obstetrics and Gynaecology. His research is primarily interested in understanding the molecular changes that occur during the development of genetic disorders, focusing on breast and ovarian cancer, and reproductive disorders. Andrew enjoys trying to keep up with advances in science.
What is InfectedNZ?
Hey, Aotearoa. It’s time we had a chat about infectious diseases and what we’re going to do about the looming antimicrobial armageddon. That’s why we’ve asked leading health, social and economic researchers, and people with personal stories, to help us get real about our vulnerability and discuss solutions. Follow their blogs right here at tepunhahamatatini.ac.nz and watch the conversation spread across social media with #infectedNZ.
Backing it all up, wherever possible, is data from the good folk at Figure.NZ. Their super duper charts are based on data sourced from public repositories, government departments, academics and corporations. Check out their #infectedNZ data board and sign-up to create your very own data board on any topic that floats your boat.

Infectious diseases in New Zealand
In the context of World Antibiotic Awareness week last week (November 14-20) and efforts to raise the awareness of infectious diseases in New Zealand, it is useful to include a discussion on viruses.
Although few treatments and vaccines are currently available for their control, the burden of disease in terms of personal affliction, loss of work or school days, hospitalisation and death is substantial. The viruses that cause human respiratory infections provide a window into the wider issues that we are dealing with regarding infectious diseases in New Zealand at present.
There are over 150 known respiratory viruses which by and large cause mild respiratory symptoms, the most common of which are the Rhinoviruses which infect the upper respiratory tract causing the common cold. Respiratory Syncytial Virus (RSV) is an important cause of more severe lower respiratory tract infections in young children, such as bronchiolitis and pneumonia, resulting in increased numbers of hospital admissions during the winter and spring months when this virus circulates in New Zealand annually. Fortunately a vaccine will be available in the near future for this virus.
Influenza is another respiratory virus which affects New Zealander’s annually. Four viruses are currently circulating: Influenza A(H3N2), A(H1N1)pdm09, Influenza B/Yamagatta and B/Victoria. Typical winter outbreaks and epidemics result in substantial illness, visits to general practitioners, school and workplace absenteeism and hospitalisation of especially young children and the elderly.
Effective interventions against influenza are available, with annual vaccination the most effective for preventing influenza infection. Vaccination needs to be annual as these viruses continue to evolve, undergoing antigenic drift, requiring frequent vaccine composition review and virus composition updating. Vaccines cannot be used in children under 6 months of age, and the best way to protect them is through vaccination of the mother before child birth. The elderly are also an issue as their immune systems are less active and they respond less vigorously to the vaccine. Regardless, vaccination is the most effective way we currently have to protect individuals against influenza.
Antivirals are effective for the treatment of influenza infections, especially if given early after the onset of symptoms. The Neuraminidase inhibitors (Tamiflu and Relenza) are the most common antivirals available. Unlike the use of antibiotics against bacterial infections, where unnecessary use contributes to the development of resistance, misuse of antivirals in general does not drive the development of antiviral resistance and other genetic mechanisms are involved when influenza viruses have developed resistance in the past.
In recent years novel respiratory viruses have caused global concern and have resulted in countries, including New Zealand establishing pandemic preparedness plans. The most recent influenza pandemic was due to the A(H1N1)pdm09 virus which emerged from pigs in Mexico in 2009. Characteristically influenza pandemics have been associated with high mortality (3% of the world’s population died during the Spanish 1918-19 pandemic) and substantial illness. However the 2009 virus was related to a virus that had circulated prior to 1957 and caused generally milder infections. Regardless, the circulation of this new virus did place substantial pressure on our health system over 2009 and the winter of 2010.
The emergence of the avian influenza A(H5N1) virus in Hong Kong in 1997, then re-emergence and spread amongst domestic poultry from late 2003 in many parts of the world remains a concern. Although human infections are rare, they are consistently associated with a 50% mortality rate. Should this virus develop the ability to be transmitted between humans, the outcome would be devastating. Another more recent avian A(H7N9) virus in poultry and other avian species in China, and the associated human infections, is also of concern.
Other novel respiratory viruses that have emerged recently are the SARS virus in China in 2003 and MERS-CoV, first identified in Saudi Arabia in 2012. Both viruses are Coronaviruses with origins in wild animal species (especially bats). Fortunately SARS was brought under control largely by vigorous implementation of hospital infection control measures. However MERS-CoV continues to cause severe human infections, largely in the Arabian Peninsula, with exposure to camels being a significant risk factor.
Although New Zealand is an island nation, it is very much part of the global community, especially with an economic focus on tourism drawing travellers from all parts of the world. For this reason we need to be aware of infectious diseases and what we can do to work towards their control and ensure that the treatments we have remain effective.
About
Lance Jennings is the Clinical Virologist for the Canterbury District Health Board. He is also a Clinical Associate Professor in the Pathology Department, University of Otago, Christchurch. He has an interest in the diagnosis of clinically relevant human viral infections and the epidemiology, treatment and control of influenza and other respiratory virus infections.
What is InfectedNZ?
Hey, Aotearoa. It’s time we had a chat about infectious diseases and what we’re going to do about the looming antimicrobial armageddon. That’s why we’ve asked leading health, social and economic researchers, and people with personal stories, to help us get real about our vulnerability and discuss solutions. Follow their blogs right here at tepunhahamatatini.ac.nz and watch the conversation spread across social media with #infectedNZ.
Backing it all up, wherever possible, is data from the good folk at Figure.NZ. Their super duper charts are based on data sourced from public repositories, government departments, academics and corporations. Check out their #infectedNZ data board and sign-up to create your very own data board on any topic that floats your boat.
A letter to the Ministry of Health
Below is a letter from Deputy Director Dr Siouxsie Wiles to the Ministry of Health requesting the Ministry’s assistance in using infectious disease data from the Public Health Surveillance website coordinated by the The Institute of Environmental Science and Research Ltd (ESR). The Ministry of Health has responded saying they are looking into the matter.
Dear [Ministry of Health officials]
My name is Siouxsie Wiles and I’m a microbiologist and Senior Lecturer at the University of Auckland. This year I am involved in organising an online campaign called InfectedNZ, to start a national data-driven conversation about infectious diseases. The campaign will run during World Antibiotic Awareness week (November 14-20). The idea is to start thinking about infectious diseases from different perspectives, and to bring together diverse people to look at the available data and write about the situation. The campaign is being run by Te Pūnaha Matatini, a Centre of Research Excellence, and Figure.NZ, a non-profit devoted to getting people to use data about New Zealand. We want to show Aotearoa New Zealand that infectious diseases are a current and future issue with health, social, economic, and environmental impacts.
The importance of our collaboration with Figure.NZ is that they pull together New Zealand’s public sector, private sector and academic data in one place and make it easy for people to use in simple graphical form for free through their website. All data is presented in charts that are designed to be compared easily with each other and constructed with as little bias as possible. Figure.NZ only use data that has a creative commons licence that allows them to publish the data on their site – this is usually the CC BY 3.0 license: https://creativecommons.org/licenses/by/3.0/nz/.
When searching for relevant data on infectious diseases in NZ, I found lots of data presented online on the ESR website (https://surv.esr.cri.nz/), produced under contract with the Ministry of Health. I was particularly interested in obtaining the data to help provide easy to understand charts for experts to use during our campaign. Unfortunately, the current licence allows personal use of the data but not for us to publish on Figure.NZ to help make it easier for people to find and visualise. Instead, there is a disclaimer that instructs users to contact ESR for other uses, such as that envisioned by this campaign (http://www.esr.cri.nz/footer/disclaimer-and-copyright/). We have tried this but the answer was no.
I would like to know what the Ministry of Health’s position is on improving access to publicly available data, like that on the ESR website, for uses like our campaign. We have no interest in manipulating this data other than to standardise the spreadsheets and to present simple visualisations from them. We think that providing usable, clear, digestible and unbiased information will help New Zealanders make better decisions, and will lead to better outcomes for all of us. I am disappointed that important public data like that published online by ESR is essentially out of bounds.
I look forward to your response.
Siouxsie

InfectedNZ: the state of the nation
Last week was World Antibiotic Awareness week, an initiative of the World Health Organization (WHO) to raise awareness and understanding of antibiotic-resistant superbugs. To follow, here at Te Pūnaha Matatini we are launching a week-long conversation about the health, social, economic, and environmental impacts of infectious diseases in Aotearoa New Zealand. Where possible, in collaboration with Figure.NZ, we’ll bring you publicly available data to help illustrate the issues. Welcome to #InfectedNZ!
Infectious diseases: complexity personified
The phrase ‘infectious diseases’ describes a multitude of life forms which differ in their genetic make-up, life-styles and habitats. They lurk, hidden and unseen, on our skin, up our noses and in our guts. On our pets and livestock, too. And amongst our plants, rivers and soils. And when some of them get into our bodies, or into our plants and animals, they can cause devastation to human and animal health, our environment, and our economy. So there is no one single threat from infectious diseases, or indeed, no simple one-size-fits-all solution. Like so much in life, the issue is complex and complicated.
But experts do all agree on one thing: we are running out of ways to treat infectious diseases.
The prediction is that without urgent action, within the next 5-10 years we could see a return to the pre-antibiotic era, when something as simple as a stubbed toe could mean amputation or death. That’s a big part of why we need to have a national conversation about infectious diseases and what the future holds.
Aotearoa New Zealand: we are not immune
Many people think of infectious diseases as a third world problem. And it’s not hard to see why when we are all surrounded by friends and family being diagnosed with various cancers or heart disease. But in the year July 2013 to June 2014, almost 91,000 Kiwis had infectious diseases listed as the primary cause for why they were hospitalised, accounting for around 8% of all hospitalisations that year. It’s also worth noting that many other people in hospital will also be battling an infectious disease as a result of having a compromised immune system, either because they’ve had surgery, or have a non-communicable disease like cancer or diabetes. These people will not feature in the numbers though, as their underlying disease would be listed as the primary cause for them being in hospital.
As you can see, two-thirds of infectious disease hospitalisations were for bacterial infections, with the major contributors being food and water-borne infections, Staphylococcus aureus (also known as Staph, or MRSA, which stands for methicillin-resistant S. aureus) and Streptococcus pyogenes (also known as Group A Strep, or sometimes, the ‘flesh-eating disease’, as this bacterium can sometimes carry an enzyme that can digest human flesh).
Fortunately, the majority of infectious diseases that Kiwis are exposed to are still treatable. In 2013, just over 1,200 (about 4%) of the 29,636 people who died that year had infectious diseases listed as the primary cause of their demise. As in the hospitalisations, the figures cover what was recorded on the death certificate which may not always be the immediate cause of death. For example, many of those who are recorded as having died of Alzheimer’s disease are more likely to have died of pneumonia or a urinary tract infection.
We’re bucking international trends, but not in a good way
As countries become more developed, their rates of infectious diseases fall, and their rates of non-communicable diseases like cancer and heart disease rise as people live longer. Most Kiwi’s will probably be surprised to find out that here in Aotearoa New Zealand we are bucking those international trends: our rates for many infectious diseases are going up, not down. We wanted to show you the data, but can’t. It is publicly available on the web but Figure.NZ were denied permission to turn it into nice charts for you to see. What we can tell you is that a study of hospital admissions over the last twenty years, carried out by Prof Michael Baker and colleagues and published in the prestigious medical journal The Lancet, showed that while overnight admissions to hospital due to non-communicable diseases have increased by 7%, those due to infectious diseases have gone up by a staggering 50% (1).
“Surely it’s them, not us?!”
What you might also be surprised to hear is that we have higher rates of many infectious diseases than the USA, Australia and the UK. And just in case the thought crosses your mind that perhaps all those infectious diseases are being imported into New Zealand by ‘foreigners’, and if we curb immigration infectious diseases will all go away…How can I put this politely?! I think you’ll find it’s a little more complicated than that!
Yes, some infectious diseases can be ‘imported’ into New Zealand by ‘foreigners’. But guess who also goes overseas? We do. In droves. According to Statistics New Zealand, in 2014 there were more than 700,000 overseas departures from Auckland Airport by resident New Zealander’s going on holiday. Another 600,000 were people going to visit friends and relatives overseas. As an island nation, we travel a lot. And each of those trips is an opportunity to bring back an invisible infectious passenger. So, unless you never want to go on holiday again, or visit friends and family overseas, let’s nip that line of thinking in the bud. The reality is, we don’t need travel or foreigners to bring infectious diseases or antibiotic-resistant superbugs to our Clean Green/100% Pure(TM) island paradise.
So, to sum up. Not only are infectious diseases becoming more widespread here, they are also becoming more difficult to treat. It’s time we stopped thinking of infectious diseases as a third world problem, and have a national conversation about how we all, the public, health workers, policymakers and the agricultural sector, can solve this crisis. I hope you’ll join us across the week to participate in this important discussion. Follow #infectedNZ on Twitter or Facebook, or leave a comment below.
Reference:
(1) “Baker MG, Barnard LT, Kvalsvig A, Verrall A, Zhang J, Keall M, Wilson N, Wall T, Howden-Chapman P (2012). Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study. Lancet. 379(9821):1112-9. doi: 10.1016/S0140-6736(11)61780-7.
About:
Dr Siouxsie Wiles is Deputy Director (Outreach and Public Engagement) of Te Pūnaha Matatini. She describes herself as a microbiologist and bioluminescence enthusiast. As Head of the Bioluminescent Superbugs Lab at the University of Auckland, Siouxsie combines her twin passions to understand infectious diseases.
What is InfectedNZ?
Hey, Aotearoa. It’s time we had a chat about infectious diseases and what we’re going to do about the looming antimicrobial armageddon. That’s why we’ve asked leading health, social and economic researchers, and people with personal stories, to help us get real about our vulnerability and discuss solutions. Follow their blogs right here at tepunhahamatatini.ac.nz and watch the conversation spread across social media with #infectedNZ.
Backing it all up, wherever possible, is data from the good folk at Figure.NZ. Their super duper charts are based on data sourced from public repositories, government departments, academics and corporations. Check out their #infectedNZ data board and sign-up to create your very own data board on any topic that floats your boat.

The New Zealand Polymath: Colenso and his contemporaries
November 16 & 17, Te Pūnaha Matatini’s Executive Manager Kate Hannah and Principal Investigator Dr Dion O’Neale are presenting at a conference on William Colenso and his contemporaries.
What: The New Zealand Polymath – Colenso and his contemporaries
When: Conference runs from 16-18 November
Where: National Library of New Zealand, Molesworth Street, Wellington
Opening address: Dabbling Dilettantes and Renaissance Men: colonial polymaths and New Zealand’s science culture.
During the opening session, Kate will present “Dabbling Dilettantes and Renaissance Men: colonial polymaths and New Zealand’s science culture.” The presentation will explore the hero narratives regarding the network of polymath-scholars who established the institutions of New Zealand’s scientific culture. Such narratives permeate New Zealand’s history and contemporary public discourse, but actively exclude the impact of those participants who are exceptions to the hero narrative, rendering them invisible.
The lecture is free and open to the public. More details>
Panel discussion: Colonial polymaths and New Zealand’s science culture
Following the address, Kate will chair a panel discussion that will problematize the impact of centering national identity within a group of ‘Renaissance men’, exploring those whose scholarly contributions are framed as dabbling distractions, and those others whose labour enabled the expansion and sharing of knowledge that typified colonial New Zealand.
The panellists are:
- Nicola Gaston, University of Auckland
- Angela Middleton, University of Otago
- Linda Tyler, University of Auckland
- Daniel Hikuroa, Ngā Pae o te Māramatanga, University of Auckland
Presentation: Colenso’s correspondence network
Thursday 17 November Dion and Kate present on Colenso’s correspondence network.
View the full conference programme>

Marsden Fund success for Te Pūnaha Matatini investigators
Seven Te Pūnaha Matatini investigators were awarded Marsden-funding this week across a broad range of research projects, from investigating Māori social systems to integrative models of species evolution.
Professor Thegn Ladefoged and Dr Dion O’Neal from the University of Auckland, and Associate Professor Marcus Frean from Victoria University Wellington will study the development of Māori social systems over time. The investigators will combine their skills in archaeology and network science – a prime example of the ability of New Zealand’s Centres of Research Excellence to connect researchers from across disciplines to tackle exciting projects. Read more>
Professor Alexei Drummond and Dr David Welch from the University of Auckland’s Department of Computer Science have received Marsden-funding to research genomes, phenotypes and fossils and integrative models of species evolution.
Dr Steffen Lippert from the University of Auckland’s Business School will be leading a project titled: “Beyond the Jury Paradox: Collective Decision-Making without Common Priors.”
Dr Daniel Hikuroa, an earth systems scientist from the University of Auckland, will be an associate investigator on a project titled “Melt inclusions as a ‘window’ through the crust: What drives the most productive region of silicic volcanism on Earth?”
Marsden Funds are highly competitive grants distributed over three years, paying for salaries, students and postdoctoral positions, institutional overheads and research consumables. The grants are managed by the Royal Society of New Zealand on behalf of the government.
In 2015, Te Pūnaha Matatini Principal Investigator Adam Jaffe from Motu Economic Research and Public Policy worked with the Royal Society of New Zealand to evaluate and identify opportunities to improve their decision-making processes around funding.
Adam demonstrated that receiving Marsden funding leads to higher productivity and impacts in terms of papers published and citations received. Adam and his team also found there is no reason to expect diminishing returns if Marsden funding were increased.
Read the Motu working paper on the findings or Te Pūnaha Matatini Director Shaun Hendy’s blog.

Māori social systems focus of novel research collaboration
Archaeology and modern network science are combining to investigate the development of Māori social networks over time as part of a new three year $705,000 Marsden-funded project.
The research draws upon the skills of archaeologist Professor Thegn Ladefoged and network scientists Dr Dion O’Neal and Associate Professor Marcus Frean from Te Pūnaha Matataini, a Centre of Research Excellence in complex systems and networks. The research team also includes Associate Professor Mark McCoy from the USA’s Southern Methodist University, and Alex Jorgensen from the University of Auckland who will use portable X-ray fluorescence to characterize and source obsidian artefacts. Assistant Professor Chris Stevenson from Virginia Commonwealth University will develop obsidian hydration dating of artefacts to establish tight chronological control of changing levels of interaction.
Professor Ladefoged from the University of Auckland explains that over centuries relatively autonomous village-based Māori groups have transformed into larger territorial hapū lineages, which later formed even larger iwi associations.
Information passed down through generations by word of mouth has traditionally provided the best evidence of these complex, dynamic changes in Māori social organisation. The research group’s novel combination of archaeological and network science skills aims to provide new insights into these social changes.
“By researching ancient obsidian tools and their movement across New Zealand we can reconstruct historical systems of inter-iwi trade,” Professor Ladefoged says.
The research group will then combine this archaeological and location data with social network analysis modelling and local iwi input to provide new insights into how Māori society was transformed from village-based groups to powerful hapū and iwi.
Network analysis will enable the group to look for patterns of how archaeological sites, artefacts and obsidian sources relate to one another, and how those relationships have changed over time, explains associate investigator Dr Dion O’Neale.
“Based on those changing relationships we can put forward hypotheses about the roles played by geography or social groupings in producing the distributions of obsidian that we observe,” Dr O’Neale says.
The collaborative research project also aims to connect or reconnect Māori with their taonga held in museums and university archaeology collections.
Te Pūnaha Matatini Director Professor Shaun Hendy says the project demonstrates the ability of New Zealand’s Centres of Research Excellence to connect and amplify the efforts of researchers across a wide range of fields and locations.
“We all know that research needs to become more interdisciplinary, but we also know that this is easier said than done,” Professor Hendy says.
“I am really pleased that Thegn and his team have taken advantage of Te Pūnaha Matatini’s diverse network of researchers to tackle such an exciting project.”